Baseline Hepatitis B Surface Antigen (Hbsag) as Predictor of Sustained Hbsag Loss in Chronic Hepatitis B Patients Treated with Pegylated Interferon-α2A and Adefovir

Abstract

Background

In this study, we aimed to identify baseline predictors of response in chronic hepatitis B patients treated with a combination of pegylated interferon (PEG-IFN)-α2a and adefovir.

Methods

We treated 92 chronic hepatitis B patients (44 hepatitis B e antigen [HBeAg]-positive and 48 HBeAg-negative) with HBV DNA>100,000 copies/ml (>17,182 IU/ ml) with PEG-IFN and adefovir for 48 weeks and followed them up for 2 years. Baseline markers for HBeAg loss, combined response (HBeAg negativity, HBV DNA levels ≤2,000 IU/ml and alanine aminotransferase [ALT] normalization) and hepatitis B surface antigen (HBsAg) loss were evaluated.

Results

Two years after the end of treatment, rates of HBeAg loss and HBsAg loss in HBeAg-positive patients were 18/44 (41%) and 5/44 (11%), respectively. In HBeAg-negative patients, rates of combined response and HBsAg loss were 12/48 (25%) and 8/48 (17%), respectively. HBeAg-negative patients with HBsAg loss had lower baseline HBsAg levels than those without HBsAg loss (mean HBsAg 2.35 versus 3.55 log₁₀ IU/ml; P<0.001). They also had lower HBV DNA levels and were more often (PEG-)IFN experienced. Baseline HBsAg was the only independent predictor of HBsAg loss (OR 0.02; P=0.01).

Conclusions

With combination therapy of PEG-IFN and adefovir for 48 weeks, a high rate of HBsAg loss was observed in both HBeAg-positive (11%) and HBeAg-negative (17%) patients 2 years after treatment ended. In HBeAg-negative patients, a low baseline HBsAg level was a strong predictor for HBsAg loss.

References

World Health Organization. Hepatitis B. World Health Organization Fact Sheet 204 (Updated August 2008. Accessed 22 October 2012.). Available from www.who.int/mediacentre/factsheets/fs204/en.

Lau

G.K.

, Piratvisuth

, Luo

K.X.

Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682–2695.

Marcellin

, Lau

G.K.

, Bonino

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206–1217.

Hadziyannis

S.J.

, Tassopoulos

N.C.

, Heathcote

E.J.

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005; 352: 2673–2681.

Janssen

H.L.

, van Zonneveld

, Senturk

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365: 123–129.

Rijckborst

, ter Borg

M.J.

, Cakaloglu

A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B. Am J Gastroenterol 2010; 105: 1762–1769.

Liu

C.J.

, Lai

M.Y.

, Chao

Y.C.

Interferon alpha-2b with and without ribavirin in the treatment of hepatitis B e antigen-positive chronic hepatitis B: a randomized study. Hepatology 2006; 43: 742–749.

Buster

E.H.

, Hansen

B.E.

, Lau

G.K.

Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 2009; 137: 2002–2009.

Bonino

, Marcellin

, Lau

G.K.

Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 2007; 56: 699–705.

10.

Piccolo

, Lenci

, Demelia

A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B. Antivir Ther 2009; 14: 1165–1174.

11.

Flink

H.J.

, van Zonneveld

, Hansen

B.E.

, de Man

R.A.

, Schalm

S.W.

, Janssen

H.L.

Treatment with peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol 2006; 101: 297–303.

12.

Buster

E.H.

, Flink

H.J.

, Simsek

Early HBeAg loss during peginterferon alpha-2b therapy predicts HBsAg loss: results of a long-term follow-up study in chronic hepatitis B patients. Am J Gastroenterol 2009; 104: 2449–2457.

13.

Buster

E.H.

, Flink

H.J.

, Cakaloglu

Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 2008; 135: 459–467.

14.

Deguchi

, Yamashita

, Kagita

Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay. J Virol Methods 2004; 115: 217–222.

15.

Ishak

, Baptista

, Bianchi

Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696–699.

16.

European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167–185.

17.

Lok

A.S.

, McMahon

B.J.

Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661–662.

18.

de Niet

, Takkenberg

R.B.

, Benayed

Genetic variation in IL28B and treatment outcome in HBeAg-positive and -negative chronic hepatitis B patients treated with Peg interferon alfa-2a and adefovir. Scand J Gastroenterol 2012; 47: 475–481.

19.

Marcellin

, Bonino

, Lau

G.K.

Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology 2009; 136: 2169–2179.

20.

Villani

, Calio

, Balestra

9-(2-Phosphonylmethoxyethyl) adenine increases the survival of influenza virus-infected mice by an enhancement of the immune system. Antiviral Res 1994; 25: 81–89.

21.

Del Gobbo

, Foli

, Balzarini

Immunomodulatory activity of 9-(2-phosphonylmethoxyethyl)adenine (PMEA), a potent anti-HIV nucleotide analogue, on in vivo murine models. Antiviral Res 1991; 16: 65–75.

22.

Wursthorn

, Lutgehetmann

, Dandri

Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006; 44: 675–684.

23.

Wang

Y.D.

, Zhao

C.Y.

, Wang

Improved efficacy by individualized combination therapy with peg IFN-a 2a and ADV in HBeAg positive chronic hepatitis B patients. Hepatogastroenterology 2012; 59: 680–686.

24.

Manesis

E.K.

, Hadziyannis

E.S.

, Angelopoulou

O.P.

, Hadziyannis

S.J.

Prediction of treatment-related HBsAg loss in HBeAG-negative chronic hepatitis B: a clue from serum HBsAg levels. Antivir Ther 2007; 12: 73–82.

25.

Jaroszewicz

, Calle

S.B.

, Wursthorn

Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol 2010; 52: 514–522.

26.

Kim

Y.J.

, Cho

H.C.

, Choi

M.S.

The change of the quantitative HBsAg level during the natural course of chronic hepatitis B. Liver Int 2011; 31: 817–823.

27.

Nguyen

, Thompson

A.J.

, Bowden

Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol 2010; 52: 508–513.

28.

Chan

H.L.

, Wong

V.W.

, Tse

A.M.

Serum hepatitis B surface antigen quantitation can refect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol 2007; 5: 1462–1468.

29.

Visvanathan

, Skinner

N.A.

, Thompson

A.J.

Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein. Hepatology 2007; 45: 102–110.

30.

, Meng

, Jiang

Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology 2009; 49: 1132–1140.

31.

Iloeje

U.H.

, Yang

H.I.

, Su

, Jen

C.L.

, You

S.L.

, Chen

C.J.

Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678–686.

32.

Chen

C.J.

, Yang

H.I.

, Su

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65–73.

33.

Yang

H.I.

, Lu

S.N.

, Liaw

Y.F.

Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347: 168–174.